Stomatológ 2021, 31(1):11-13 | DOI: 10.69658/sto.2021.003

Osteonecrosis of the maxilla caused by bisphosphonates

Anna Birková1, Tomáš Klabník2, Peter Badanič2, Lívia Sladká2, Beáta Bolerázska3, Beáta Hubková1, Mária Mareková1, Beáta Čižmárová1,*
1 Ústav lekárskej a klinickej biochémie UPJŠ LF, Tr. SNP 1, Košice
2 I. stomatologická klinika UPJŠ LF a UNLP, Oddelenie ústnej, čeľustnej a tvárovej chirurgie, Tr. SNP 1, Košice
3 I. stomatologická klinika UPJŠ LF a UNLP, Tr. SNP 1, Košice

Bisphosphonates are antiresorptive drugs affecting mainly osteoclasts and thus maintaining the bone density and strength. The one of the most important property of bisphosphonates is their very high affinity to bone tissue and subsequent deposition in bone tissue, thus ensuring a high concentration in bone tissues. The osteonecrosis of the maxilla is a newly described phenomena in connection with bisphosphonate therapy. The first case describing osteonecrosis of the maxilla was published in 2003. Since then, sufficient and increased attention has been paid to this problem.

Keywords: osteonecrosis, bisphosphonates, bone, maxilla

Published: June 15, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Birková A, Klabník T, Badanič P, Sladká L, Bolerázska B, Hubková B, et al.. Osteonecrosis of the maxilla caused by bisphosphonates. Stomatológ. 2021;31(1):11-13. doi: 10.69658/sto.2021.003.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. ADAM, Z., KOZUMPLÍKOVÁ, M., POUR, L., MACHÁLKA, M.: Osteonekróza čelisti v průběhu léčby mnohočetného myelomu. Vnitř Lék. 2006; 52 (2): 176-180.
    2. CAMPISI, G., FEDELE, S., FUSCO, V., PIZZO, G., Di FEDE, O., BEDOGNI, A.: Epidemiology, clinical manifestations, risk reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agents. Future Oncol. 2014; 10 (2): 257-275. Go to original source... Go to PubMed...
    3. CREMERS, S. C., PILLAI, G., PAPAPOULOS, S. E.: Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clinical Pharmacokinetics 2005; 44(6): 551-570. Go to original source... Go to PubMed...
    4. DRAKE, M. T., CLARKE, B. L., KHOSLA, S.: Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008; 83 (9): 1032-1045. Go to original source... Go to PubMed...
    5. DUNFORD, J. E., THOMPSON, K., COXON, F. P., LUCKMAN, S. P., HAHN, F. M., POULTER, C. D, EBETINO, F. H., ROGERS, M. J.: Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001; 296 (2): 235-242. Go to original source...
    6. GAVALDÁ, C., BAGÁN, J. V.: Concept, diagnosis and classification of bisphosphonate-associated osteonecrosis of the jaws. A review of the literature. Med Oral Patol Oral Cir Bucal. 2016; 21 (3): 260-270. Go to original source... Go to PubMed...
    7. JANOVSKÁ, Z.: Bisphosphonate-related osteonecrosis of the jaws.A s evere side effect of bisphosphonate therapy, Acta Medica. 2012; 55: 111-115. Go to original source... Go to PubMed...
    8. MARX, R. E.: Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003; 61 (9): 1115-1117. Go to original source... Go to PubMed...
    9. POUR, L., ADAM, Z., HÁJEK, R.: Ibandronat. Klinická onkologie. 2005; 18 (5): 172-177.
    10. POUR, L., HÁJEK, R., ADAM, Z.: Výběr bisfosfonátu k léčbě kostního postižení u pacientů s prokázanou malignitou. Klinická onkologie. 2005; 18 (6): 210-216.
    11. RASMUSSON, L., ABTAHI, J.: Bisphosphonate associated osteonecrosis of the jaw: an update on pathophysiology, risk factors, and treatment. Int J Dent. 2014; 2014: 471035. Go to original source... Go to PubMed...
    12. RUGGIERO, S. L., DODSON, T. B., FANTASIA, J., GOODAY, R., AGHALOO, T., MEHROTRA, B., O'RYAN, F.: American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update. J Oral Maxillofac Surg. 2014; 72 (10): 1938-1956. Erratum in: J Oral Maxillofac Surg. 2015 Jul; 73 (7): 1440. Erratum in: J Oral Maxillofac Surg. 2015 Sep; 73 (9): 1879. Go to original source... Go to PubMed...
    13. RUSSELL, R. G., ROGERS, M. J., FRITH, J. C., LUCKMAN, S. P., COXON, F. P., BENFORD, H. L., CROUCHER, P. I., SHIPMAN, C., FLEISCH, H. A.: The pharmacology of bisphosphonates and new insights into their mechanisms of action. J Bone Miner Res. 1999; 2: 53-65. Go to original source... Go to PubMed...
    14. RUSSELL, R. G.: Bisphosphonates: from bench to bedside. Ann N Y Acad Sci. 2006; 1068: 367-401. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content